aTyr Pharma ATYR 深 滬
等待開盤 10-14 09:30:00 美东时间
0.9658
-0.094
-8.89%
華盛通- 最 高1.08
- 今 開1.065
- 成交量 947.24万股
- 最 低 0.95
- 昨 收 1.06
- 總市值 8596.04万
- 52周最高 7.2904
- 市盈率 靜 --
- 換手率 10.64%
- 52周最低 0.6816
- 委 比 -55.69%
- 總股本 8900.44万
- 歷史最高 396.06
- 量 比 0.79
- 振 幅 12.26%
- 歷史最低 0.6816
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Symbotic, Serve Robotics, AeroVironment, aTyr Pharma, Cummins: Insider Moves Unveiled
Insiders have been trading these 5 stocks: (($SYM)), (($SERV)), (($AVAV)), (($A...
10-11 21:00
aTyr Pharma Faces Legal Storm After Trial Failure
In a dramatic turn of events, aTyr Pharma, Inc. finds itself at the center of a...
10-10 21:15
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
SAN FRANCISCO, Oct. 9, 2025 /PRNewswire/ -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's s...
10-10 10:18
aTyr Pharma Highlights Trial Results For Efzofitimod, Aiming To Ease Fatigue And Steroid Use In Pulmonary Sarcoidosis
aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today
09-30 17:32
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
aTyr Pharma announced positive results from its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis patients. The study showed significant improvements in fatigue and general health scores compared to placebo, though it missed its primary endpoint of reducing oral corticosteroid use. Efzofitimod demonstrated potential to improve multiple disease-related outcomes and reduce reliance on chronic steroids, offering hope for better quality ...
09-30 09:30
Benzinga Bulls And Bears: Intel, FedEx, Cracker Barrel — And Markets Close At Record Highs
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
09-20 20:01
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Check-Cap (NASDAQ:CHEK) shares rose 225.1% to $2.42 during Monday's re...
09-16 01:06
Court battle over Citgo parent auction kicks off in Delaware
A U.S. court in Delaware on Monday begins a pivotal hearing to decide the outcome of the auction of PDV Holding, parent of Venezuela-owned Citgo Petroleum, with creditors and bidders clashing over who...
09-15 21:22
aTyr Pharma shares are trading higher after Cantor Fitzgerald issued a Buy rating on the stock.
aTyr Pharma shares are trading higher after Cantor Fitzgerald issued a Buy rati...
09-13 01:27
